Medicare Enrolled
Dr. Martin Belkin, D.O.
Neurology · Farmington Hills, MI
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Belkin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Belkin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Belkin
Dr. Martin Belkin is a neurology specialist in Farmington Hills, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Belkin performed 169,162 Medicare services across 1,846 unique beneficiaries.
Between the years covered by Open Payments, Dr. Belkin received a total of $759,448 from 45 pharmaceutical and/or device companies across 1208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Belkin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in MI
$759,448 industry payments
Medicare Practice Summary
Medicare Utilization ↗169,162
Medicare services
Top 0% in MI for neurology
1,846
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,458 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, natalizumab, 1 mg | 72,300 | $17 | $50 |
| Ocrelizumab infusion (Ocrevus) for MS | 54,000 | $42 | $127 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 19,960 | $37 | $114 |
| Injection, eptinezumab-jjmr, 1 mg | 18,900 | $13 | $35 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
738 | $47 | $181 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
642 | $86 | $205 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
505 | $11 | $42 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
417 | $15 | $65 |
| Methylprednisolone injection, up to 125 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg. |
271 | $4 | $19 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
205 | $1 | $3 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
168 | $64 | $112 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
165 | $1 | $8 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
139 | $0 | $2 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
130 | $1 | $10 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
107 | $102 | $213 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
104 | $87 | $336 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
95 | $119 | $270 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
73 | $122 | $264 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
47 | $10 | $49 |
| Electromyography of arm or leg muscles A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them. |
41 | $77 | $217 |
| EEG, extended monitoring A test that records electrical activity in the brain while the patient is both awake and asleep. |
34 | $345 | $1,017 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
28 | $19 | $84 |
| Awake and drowsy EEG A test that records electrical activity in the brain while the patient is awake and drowsy. |
22 | $294 | $852 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $60 | $141 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
15 | $3 | $8 |
| Nerve conduction studies, 5-6 tests A series of 5 to 6 tests that measure how well nerves send electrical signals. The procedure evaluates nerve function and helps identify damage or dysfunction. |
12 | $103 | $315 |
| EEG monitoring, 61-84 hours with review This procedure involves continuous monitoring of brain wave activity for 61 to 84 hours. A healthcare professional reviews the data and provides a report. |
11 | $207 | $597 |
| Nerve conduction study, 9-10 studies A diagnostic test that measures how well nerves send electrical signals. It involves performing 9 to 10 separate nerve conduction studies to evaluate nerve function. |
11 | $171 | $523 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.8% high complexity
66.4% medium
0.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$759,448
Total received (2018-2024)
Avg $108,493/year across 7 years
Top 1% in MI for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
45
Companies
1,208
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$695,553 (91.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$60,367 (7.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,528 (0.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$131,967
2023
$125,218
2022
$96,884
2021
$58,410
2020
$72,001
2019
$125,752
2018
$149,215
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
TG Therapeutics, Inc.
$37,191
EMD Serono, Inc.
$26,630
Genentech USA, Inc.
$15,111
Alexion Pharmaceuticals, Inc.
$12,872
GENZYME CORPORATION
$12,052
Biogen, Inc.
$11,435
ARGENX US, INC.
$7,109
Amgen Inc.
$6,956
E.R. Squibb & Sons, L.L.C.
$1,620
ABBVIE INC.
$308
Celgene Corporation
$300
Novartis Pharmaceuticals Corporation
$251
Sumitomo Pharma America, Inc.
$45
PFIZER INC.
$32
CATALYST PHARMACEUTICALS, INC.
$31
Eisai Inc.
$24
Top 3 companies account for 59.8% of 2024 payments
All-time payments by company (2018-2024) ›
EMD Serono, Inc.
$127,657
Genentech USA, Inc.
$118,415
GENZYME CORPORATION
$118,278
Biogen, Inc.
$116,164
Alexion Pharmaceuticals, Inc.
$58,884
TG Therapeutics, Inc.
$42,169
Celgene Corporation
$34,759
E.R. Squibb & Sons, L.L.C.
$31,223
TG THERAPEUTICS, INC.
$23,494
SANOFI-AVENTIS U.S. LLC
$22,345
Novartis Pharmaceuticals Corporation
$13,439
Horizon Therapeutics plc
$9,518
Allergan, Inc.
$8,745
Amgen Inc.
$7,136
ARGENX US, INC.
$7,109
Teva Pharmaceuticals USA, Inc.
$6,994
Acorda Therapeutics, Inc
$5,694
Merck KGaA
$3,300
Genentech, Inc.
$2,019
ABBVIE INC.
$308
AbbVie Inc.
$298
PFIZER INC.
$208
Supernus Pharmaceuticals, Inc.
$196
Otsuka America Pharmaceutical, Inc.
$136
Sumitomo Pharma America, Inc.
$117
Eisai Inc.
$110
Grifols USA, LLC
$92
EISAI INC.
$87
Sunovion Pharmaceuticals Inc.
$83
Biohaven Pharmaceuticals, Inc.
$81
Avanir Pharmaceuticals, Inc.
$73
UCB, Inc.
$61
Lilly USA, LLC
$36
CATALYST PHARMACEUTICALS, INC.
$31
Promius Pharma LLC
$26
US WorldMeds, LLC
$22
ACADIA Pharmaceuticals Inc
$20
Lundbeck LLC
$19
Biohaven Pharmaceutical Holding Company Ltd.
$18
Adamas Pharmaceuticals, Inc.
$17
Allergan Inc.
$15
Mallinckrodt Hospital Products Inc.
$14
Mallinckrodt LLC
$13
Zogenix Inc.
$13
Assertio Therapeutics, Inc.
$11
Top 3 companies account for 48.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AIMOVIG · AJOVY · AMPYRA · APTIOM · AUBAGIO · AUSTEDO · Aimovig · BOTOX · BRIUMVI · Briviact · COMIRNATY · COPAXONE · DISEASE STATE · EMGALITY · Enspryng · Evobrutinib · FYCOMPA · Fintepla · Fycompa · GILENYA · GOCOVRI · GRALISE · Gamunex-C · INBRIJA · KESIMPTA · LEMTRADA · LUMIZYME · LYRICA · Leqembi · MAVENCLAD · MAYZENT · MS DISEASE STATE · MYOBLOC · Mavenclad · NORTHERA · NUEDEXTA · NUPLAZID · NURTEC ODT · Nuedexta · OCREVUS · OXTELLAR XR · Ocrevus · Ozanimod · PAXLOVID · QULIPTA · Rebif · Rituxan · SOLIRIS · SPINRAZA · Soliris · TECFIDERA · TROKENDI XR · TYSABRI · Tysabri · UBRELVY · ULTOMIRIS · UPLIZNA · VUMERITY · VYVGART · ZEMBRACE SYMTOUCH · ZEPOSIA · Zembrace
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (92%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in neurology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for neurology in MI.
Geographic Context
Neurologists within 10 mi
356
Per 100K population
28.0
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL - FARMINGTON HILLS
2.9 mi
2.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Belkin is a mixed practice specialist, with above-average Medicare volume (top 0% in MI), with speaking/promotional industry engagement in the top 1% of MI peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Belkin experienced with injection, natalizumab, 1 mg?
Based on Medicare claims data, Dr. Belkin performed 72,300 injection, natalizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Belkin receive payments from pharmaceutical companies?
Yes. Dr. Belkin received a total of $759,448 from 45 companies across 1,208 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Belkin's costs compare to other neurologists in Farmington Hills?
Dr. Belkin's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Belkin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Farmington Hills
Browse neurologists in Farmington Hills ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in MI
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in MI
Which MI neurologists receive the most from drug and device companies.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology